A low grade carcinoma of the kidney characterized by the presence of tubules which are separated by mucinous stroma. Often the tubular structures have a spindle cell appearance. Patients are usually a...
Comprehensive, easy-to-understand information about this condition
How we create this content →The documentation for mucinous tubular and spindle renal cell carcinoma is limited primarily due to its rarity, which affects fewer than 1 in 100,000 individuals. This rarity leads to fewer systematic clinical studies and a lack of comprehensive phenotype documentation. As a result, understanding of the condition is still evolving, and ongoing research may provide more insights in the future.
To navigate your care for mucinous tubular and spindle renal cell carcinoma, it is recommended to seek a urologist or oncologist with expertise in renal cancers. You may also consider contacting the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov for resources and support. Although no patient organizations are currently identified, participating in any future natural history studies or registries could provide valuable insights into your condition.
There are several orphan drugs designated for mucinous tubular and spindle renal cell carcinoma, including bevacizumab, sorafenib, and temsirolimus, which are FDA-approved. Additionally, there are multiple drugs in development, such as antiangiogenic components extracted from marine cartilage and recombinant human interleukin-12. Unfortunately, no clinical trial data is currently available. For updates on ongoing research, you can search ClinicalTrials.gov for relevant studies.
Actionable guidance for navigating care for mucinous tubular and spindle renal cell carcinoma
To navigate your care for mucinous tubular and spindle renal cell carcinoma, it is recommended to seek a urologist or oncologist with expertise in renal cancers. You may also consider contacting the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov for resources and support. Although no patient organizations are currently identified, participating in any future natural history studies or registries could provide valuable insights into your condition.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The documentation for mucinous tubular and spindle renal cell carcinoma is limited primarily due to its rarity, which affects fewer than 1 in 100,000 individuals. This rarity leads to fewer systematic clinical studies and a lack of comprehensive phenotype documentation. As a result, understanding of the condition is still evolving, and ongoing research may provide more insights in the future.
To navigate your care for mucinous tubular and spindle renal cell carcinoma, it is recommended to seek a urologist or oncologist with expertise in renal cancers. You may also consider contacting the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov for resources and support. Although no patient organizations are currently identified, participating in any future natural history studies or registries could provide valuable insights into your condition.
There are several orphan drugs designated for mucinous tubular and spindle renal cell carcinoma, including bevacizumab, sorafenib, and temsirolimus, which are FDA-approved. Additionally, there are multiple drugs in development, such as antiangiogenic components extracted from marine cartilage and recombinant human interleukin-12. Unfortunately, no clinical trial data is currently available. For updates on ongoing research, you can search ClinicalTrials.gov for relevant studies.
Actionable guidance for navigating care for mucinous tubular and spindle renal cell carcinoma
To navigate your care for mucinous tubular and spindle renal cell carcinoma, it is recommended to seek a urologist or oncologist with expertise in renal cancers. You may also consider contacting the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov for resources and support. Although no patient organizations are currently identified, participating in any future natural history studies or registries could provide valuable insights into your condition.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The documentation for mucinous tubular and spindle renal cell carcinoma is limited primarily due to its rarity, which affects fewer than 1 in 100,000 individuals. This rarity leads to fewer systematic clinical studies and a lack of comprehensive phenotype documentation. As a result, understanding of the condition is still evolving, and ongoing research may provide more insights in the future.
To navigate your care for mucinous tubular and spindle renal cell carcinoma, it is recommended to seek a urologist or oncologist with expertise in renal cancers. You may also consider contacting the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov for resources and support. Although no patient organizations are currently identified, participating in any future natural history studies or registries could provide valuable insights into your condition.
There are several orphan drugs designated for mucinous tubular and spindle renal cell carcinoma, including bevacizumab, sorafenib, and temsirolimus, which are FDA-approved. Additionally, there are multiple drugs in development, such as antiangiogenic components extracted from marine cartilage and recombinant human interleukin-12. Unfortunately, no clinical trial data is currently available. For updates on ongoing research, you can search ClinicalTrials.gov for relevant studies.
Actionable guidance for navigating care for mucinous tubular and spindle renal cell carcinoma
To navigate your care for mucinous tubular and spindle renal cell carcinoma, it is recommended to seek a urologist or oncologist with expertise in renal cancers. You may also consider contacting the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov for resources and support. Although no patient organizations are currently identified, participating in any future natural history studies or registries could provide valuable insights into your condition.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Consider asking your healthcare providers these condition-specific questions
European rare disease database
Genetic and Rare Diseases Info Center
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.